The use of low molecular weight heparin in the initial management of patients with deep vein thrombosis.
Low molecular weight heparins (LMWH) have been found to be a safe and effective treatment for the prevention of venous thromboembolism. Recent clinical trials have further investigated the use of this class of drugs in the initial treatment of venous thromboembolism. The interest surrounding this new group of anticoagulants is sparked by the reduction in intensive resources required to safely administer this medication in comparison to the traditional treatment with heparin. Low molecular weight heparins do not require laboratory monitoring and can be given once or twice a day by subcutaneous injection, thereby allowing safe administration in the home. The potential cost savings incurred is timely in light of cost containment needs surrounding the current health care climate.
Betten
K C
KC
Hospital of the University of Pennsylvania, Surgical Trauma ICU, USA.
D017046:Cost Savings; D004334:Drug Administration Schedule; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D017048:Health Care Costs; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D006699:Home Care Services; D006801:Humans; D007279:Injections, Subcutaneous; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000191:economics
D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight